TY - JOUR
T1 - Self-injectable extended release formulation of Remdesivir (SelfExRem)
T2 - A potential formulation alternative for COVID-19 treatment
AU - Patki, Manali
AU - Palekar, Siddhant
AU - Reznik, Sandra
AU - Patel, Ketan
N1 - Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/3/15
Y1 - 2021/3/15
N2 - There has been a growing and evolving research to find a treatment or a prevention against coronavirus 2019 (COVID-19). Though mass vaccination will certainly help in reducing number of COVID-19 patients, an effective therapeutic measure must be available too. Intravenous remdesivir (RDV) was the first drug receiving Food and Drug Administration (FDA) approval for the treatment of COVID-19. However, in a pandemic like COVID-19, it is essential that drug formulations are readily available, affordable and convenient to administer to every patient around the globe. In this study, we have developed a Self-injectable extended release subcutaneous injection of Remdesivir (SelfExRem) for the treatment of COVID-19. As opposed to intravenous injection, extended release subcutaneous injection has the benefits of reducing face-to-face contact, minimizing hospitalization, reducing dosing frequency and reducing overall health care cost. SelfExRem was developed using a biodegradable polymer, poly(lactic-co-glycolic acid) (PLGA), dissolved in a biocompatible vehicle. Six different batches were formulated using 2 different grades of low molecular weight PLGA and 3 different PLGA concentration. The force of injection of various polymeric solutions through 23–30-gauge needles were analyzed using a TA.XTplus texture analyzer. The time required for injection was evaluated both manually and by using an autoinjector. In vitro release of all the batches were carried out in 1% v/v tween 80 in phosphate buffer saline. The study indicated that SelfExRem developed with 15% w/v PLGA (75:25) provided a steady release of drug for 48 h and may be a breakthrough approach for the treatment of COVID-19.
AB - There has been a growing and evolving research to find a treatment or a prevention against coronavirus 2019 (COVID-19). Though mass vaccination will certainly help in reducing number of COVID-19 patients, an effective therapeutic measure must be available too. Intravenous remdesivir (RDV) was the first drug receiving Food and Drug Administration (FDA) approval for the treatment of COVID-19. However, in a pandemic like COVID-19, it is essential that drug formulations are readily available, affordable and convenient to administer to every patient around the globe. In this study, we have developed a Self-injectable extended release subcutaneous injection of Remdesivir (SelfExRem) for the treatment of COVID-19. As opposed to intravenous injection, extended release subcutaneous injection has the benefits of reducing face-to-face contact, minimizing hospitalization, reducing dosing frequency and reducing overall health care cost. SelfExRem was developed using a biodegradable polymer, poly(lactic-co-glycolic acid) (PLGA), dissolved in a biocompatible vehicle. Six different batches were formulated using 2 different grades of low molecular weight PLGA and 3 different PLGA concentration. The force of injection of various polymeric solutions through 23–30-gauge needles were analyzed using a TA.XTplus texture analyzer. The time required for injection was evaluated both manually and by using an autoinjector. In vitro release of all the batches were carried out in 1% v/v tween 80 in phosphate buffer saline. The study indicated that SelfExRem developed with 15% w/v PLGA (75:25) provided a steady release of drug for 48 h and may be a breakthrough approach for the treatment of COVID-19.
KW - Covid19
KW - In situ depot formulations
KW - Long-acting injectables
KW - Remdesivir
KW - SARS-CoV2
UR - http://www.scopus.com/inward/record.url?scp=85100642173&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100642173&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2021.120329
DO - 10.1016/j.ijpharm.2021.120329
M3 - Article
C2 - 33540028
AN - SCOPUS:85100642173
SN - 0378-5173
VL - 597
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
M1 - 120329
ER -